GraniteShares 2x Long COIN Daily ETF vs Eli Lilly And Co — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.18, while Eli Lilly And Co trades at $1,152.44 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while GraniteShares 2x Long COIN Daily ETF pays none. Which is the better fit depends on your goals.
| CONL | LLY | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $64.57 | $1.24K |
52-Week Low | $4.09 | $625.65 |
Market Cap | — | $1.03T |
Enterprise Value | — | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.85, down 2.02% on the day, reflecting a challenging year-to-date performance. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, with significant losses tied to Coinbase stock swings and leveraged daily resets.
The outlook remains highly speculative, offering potential for explosive gains if Bitcoin rallies but carrying substantial risk from daily leverage decay and Coinbase volatility. Investors face amplified losses in downturns, making this suitable only for short-term traders with high risk tolerance.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →